KinderPharm Raises $1 Million to Further Advance Pediatric Drug Development

KinderPharm, a full-service contract research organization (CRO) dedicated exclusively to pediatric drug development, has raised $1 million from a Series A comprised of individuals, companies and angel investors. The $1 million investment will be used to further advance the clinical development of new medicines for children.

Exton, PA, August 13, 2015 --( Bringing Better Medicines to Children

The recently changed pharmaceutical industry’s perspective – as a result of legislative initiatives in both the US and Europe, and the increasing pressure from patients’ groups – created great opportunities for pediatric drug development. "The Pediatric Center of Excellence" model is a unique resource of pediatricians, pharmacometricians, regulatory, drug safety and formulation scientists that develop pediatric drugs through all stages of development. The seasoned teams bring expertise and insight to pharmaceutical companies of all sizes to help effectively navigate the complex pediatric regulatory environments in the US and Europe. With partners the company can design, manage and conduct all aspects of pediatric product development including:
- Waivers and deferrals
- Age appropriate pediatric formulations
- Juvenile toxicology studies
- Protocol design
- Dose extrapolation
- PK/PD modeling and simulation
- Population PK/sparse sampling strategies
- PDP, PSP and PIP applications
- Pediatric clinical trials
- Regulatory strategy and submissions

For further information, please contact:
- Martin Graham, PhD, Chief Executive Officer, (610) 458-1052
- Janet Welsko, Chief Operating Officer, (610) 458-1052
- Lynda Graham, MBA, Chief Financial Officer, (610) 458-1052

For media inquiries, please contact:
- Kristin Liezenga, Business Development Executive, (610) 458-1502
KinderPharm LLC
Lynda Graham